In 1841 patients with increased-risk clear-cell renal-cell carcinoma, adjuvant pembrolizumab plus belzutifan vs pembrolizumab alone improved disease-free survival (HR 0.72; 24-month 80.7% vs 73.7%); interim overall survival did not differ. Grade ≥3 events 52.1% vs 30.2%.
RCTn = 1,841
Choueiri et al. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma